Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837

Business Wire Thursday, 16 May 2019
DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: DEINOVE (Paris:ALDEI) (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, announced that all the conditions are in place for the upcoming start of the Phase II trial testing the antibiotic candidate DNV3837 for the treatment of Clostridioides difficile infections. DNV3837 is a first-in-class antibiotic candida
0
shares
ShareTweetSavePostSend
 

You Might Like


Recent related news from verified sources

Arbutus Biopharma shares soar on Phase 1a/1b trial for its AB-729 hepatitis B drug

Arbutus Biopharma Corporation (NASDAQ:ABUS), an industry-leading hepatitis B Virus (HBV) therapeutic solutions company, announced news Thursday that it has...
Proactive Investors Also reported by •Business WireGlobeNewswire

Xenikos Announces IND Clearance by the FDA for a Pivotal Phase 3 Trial Using T-Guard(R) for Treating Steroid-refractory Acute GVHD

Xenikos Announces IND Clearance by the FDA for a Pivotal Phase 3 Trial Using T-Guard(R) for Treating Steroid-refractory Acute GVHD
*NIJMEGEN, NETHERLANDS / ACCESSWIRE / June 11, 2019 /* The Dutch company Xenikos B.V., which develops innovative immunotherapies for treating patients with...
Accesswire Also reported by •Business Wire

OSE Immunotherapeutics: Continuation of “Atalante 1” Phase 3 Clinical Trial of Tedopi® in NSCLC Patients Post Checkpoint Inhibitor Failure Following IDMC Recommendation

OSE Immunotherapeutics: Continuation of “Atalante 1” Phase 3 Clinical Trial of Tedopi® in NSCLC Patients Post Checkpoint Inhibitor Failure Following IDMC Recommendation
NANTES, France--(BUSINESS WIRE)--Continuation of “Atalante 1” Phase 3 Clinical Trial of Tedopi® in NSCLC Patients Post Checkpoint Inhibitor Failure...
Business Wire Also reported by •GlobeNewswire

Lumosa to Initiate Phase 2 Human Clinical Trial in the US and Taiwan for Its LT3001, A Novel Drug for the Treatment of Acute Ischemic Stroke

Lumosa to Initiate Phase 2 Human Clinical Trial in the US and Taiwan for Its LT3001, A Novel Drug for the Treatment of Acute Ischemic Stroke
TAIPEI, Taiwan, June 13, 2019 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; code: 6535.TWO) announced that the company is ready to commence the Phase 2 proof of...
PR Newswire Asia Also reported by •Business Wire

Other recent news in Press Releases

Progress SOFTWARE Announces Details for Fiscal Second Quarter Earnings Release and Conference CallAmazon Studios, Endgame ENTERTAINMENT Begin Production on Mike Cahill’s Bliss Starring Salma Hayek and Owen Wilson
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.